Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2
Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S78
DOI: 10.1055/s-0044-1785390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Juan M. Maldonado und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Is tirzepatide (TZP 5, 10, 15mg) efficacious in reducing HbA1c and body weight (BW) compared to placebo (PBO) and semaglutide 1mg (SEMA) in people with type 2 diabetes (T2D) irrespective of baseline beta-cell function?
Method
Exploratory post-hoc analyses of people with T2D controlled by diet and exercise [SURPASS 1 (PBO)] and Metformin [SURPASS-2 (SEMA)] examined changes from baseline in HbA1c and BW at 40 weeks across HOMA2-B (C-peptide) and HOMA2-IR (insulin) quartiles (Q) from low (lower beta-cell function/insulin resistance) (Q1) to high (Q4) as assessed by mixed model repeated measures (MMRM).
Results
HbA1c reductions were greater with all TZP doses than PBO or SEMA within each HOMA2-B and HOMA2-IR baseline Q. HbA1c reductions were largest in people within HOMA-2B Q1, yet similar across all HOMA2-IR Qs. BW reductions were greater across Qs with all TZP doses (ranging from 6%-14%) than PBO (up to 2%) or SEMA (up to 7%).
Conclusion
TZP was more efficacious than PBO or SEMA in reducing HbA1c and BW across a spectrum of pancreatic beta-cell function, notably achieving greater glycemic improvement in people with markers of diminished pancreatic beta cell function at baseline. Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Maldonado, J. M., Block, C. D., Frias, J., Lee, C. J., Brown, K., Wang, H., Thomas, M. K., & Forst, T. (2024). Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2. Diabetologie und Stoffwechsel, 19(S 01 S 01), S78. https://doi.org/10.1055/s-0044-1785390
Vancouver
Maldonado JM, Block CD, Frias J, Lee CJ, Brown K, Wang H, et al. Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2. Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S78. doi:10.1055/s-0044-1785390
BibTeX
@article{Maldonado2024,
author = {Maldonado, Juan M. and Block, Christophe De and Frias, Juan and Lee, Clare J. and Brown, Katelyn and Wang, Hui and Thomas, Melissa K. and Forst, Thomas},
title = {Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-2},
journal = {Diabetologie und Stoffwechsel},
year = {2024},
volume = {19},
number = {S 01 S 01},
pages = {S78},
doi = {10.1055/s-0044-1785390}
}
EUVIMED